TrialJournal of the American Heart Association2023

Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial.

Shaun G Goodman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.